Catalyst Event
Merck and Co Inc (MRK) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
6/8/2026, 12:00:00 AM
Merck and partner Gilead announced positive topline results from two Phase 3 trials (ISLEND-1 and ISLEND-2) for their investigational, oral, once-weekly HIV treatment, islatravir/lenacapavir, on June 8, 2026; a >10% price impact is expected.
Korean Translation
Merck와 파트너인 Gilead가 공동 개발 중인 경구용 주 1회 HIV 치료제의 3상 임상 2건(ISLEND-1, ISLEND-2)에서 긍정적인 결과를 2026년 6월 8일 발표함. 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Kinder Morgan Inc. (KMI) · Other
James Holland, Chief Operating Officer, is set to retire, effective September 4, 2026. Ken Grubb, currently VP and Chief Project Officer, will succeed him as COO. The transition was announced on April 22, 2026. Impact is estimated at 1% due to the planned nature of the succession scheduled.
9/4/2026, 12:00:00 AM
HEICO Corp (HEI) · Earnings Release
Q3 2026 earnings release on 2026-08-24 scheduled.
8/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Q2 FY2027 earnings release scheduled; medium impact from financial updates expected.
8/20/2026, 12:00:00 AM
Target Corp (TGT) · Earnings Release
Q2 2026 earnings release on August 19, 2026, with analysts forecasting an EPS of approximately $2.21-$2.25; low impact estimated as the market typically prices in consensus expectations prior to the release expected.
8/19/2026, 12:00:00 AM
CoreWeave Inc (CRWV) · Earnings Release
Q2 2026 earnings release for August 18, 2026, is of high importance as such releases often cause >10% price impact; event scheduled.
8/18/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Earnings Release
Q2 2026 earnings release and conference call on August 18, 2026. Estimated price impact ~5% as earnings releases typically drive significant volatility; scheduled.
8/18/2026, 12:00:00 AM